FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity

Disclosure: C.L. Roth: Other; Self; Study funding from Rhythm Pharmaceuticals, Inc. A.H. Shoemaker: Advisory Board Member; Self; Rhythm Pharmaceuticals, Inc., Saniona. Other; Self; Study funding from Rhythm Pharmaceuticals, Inc. M. Gottschalk: Advisory Board Member; Self; Rhythm Pharmaceuticals, Inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Christian L, Shoemaker, Ashley H, Gottschalk, Michael, Miller, Jennifer L, Yuan, Guojun, Malhotra, Sonali, Scimia, Cecilia, McCormack, Shana, Jennifer Abuzzahab, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Adipose Tissue, Appetite, & Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554448/
http://dx.doi.org/10.1210/jendso/bvad114.075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554448/
http://dx.doi.org/10.1210/jendso/bvad114.075

Ejemplares similares